BeOne Medicines AG

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF off TTM FCF of $1.33B (TTM revenue $6.13B, TTM OCF $1.48B): FCF growth of 20/20/14/14/14/9/9/9/5/5 percent across years 1-10, 3% terminal growth, 9% discount rate, giving PV of explicit FCF approximately $17.4B plus PV of terminal value approximately $29.4B = EV approximately $46.8B, plus net cash of $3.05B = equity value approximately $49.8B, divided by 113.70M shares.

Reasoning: BeOne Medicines (primary Nasdaq listing ONC, which BEIGF's unsponsored OTC line tracks 1:1) is now solidly cash-generative (TTM net income $656M, FCF $1.33B) on the back of BRUKINSA's continued global share gains, so a straightforward operating-cash-flow DCF with a decelerating growth path is appropriate rather than a speculative pipeline rNPV.